FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162854541> ?p ?o ?g. }

• W2162854541 endingPage "96" @default.
• W2162854541 startingPage "88" @default.
• W2162854541 abstract "Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab-the standard adjuvant treatment. We investigated the efficacy and safety of adjuvant lapatinib for patients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after diagnosis.This study was a placebo-controlled, multicentre, randomised phase 3 trial. Women outpatients from 405 [corrected] centres in 33 countries [corrected] with HER2-positive early-breast cancer who had previously received adjuvant chemotherapy but not trastuzumab were randomly assigned (1:1) to receive daily lapatinib (1500 mg) or daily placebo for 12 months. Randomisation was done with a computer-generated sequence, stratified by time since diagnosis, lymph node involvement at diagnosis, and tumour hormone-receptor status. Investigators, site staff, and patients were masked to treatment assignment. The primary endpoint was disease-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00374322.Between August, 2006, and May, 2008, 3161 women were enrolled and 3147 were assigned to lapatinib (n=1571) or placebo (n=1576). After a median follow-up of 47·4 months (range 0·4-60·0) in the lapatinib group and 48·3 (0·7-61·3) in the placebo group, 210 (13%) disease-free survival events had occurred in the lapatinib group versus 264 (17%) in the placebo group (hazard ratio [HR] 0·83, 95% CI 0·70-1·00; p=0·053). Central review of HER2 status showed that only 2490 (79%) of the randomised women were HER2-positive. 157 (13%) of 1230 confirmed HER2-positive patients in the lapatinib group and in 208 (17%) of 1260 in the placebo group had a disease-free survival event (HR 0·82, 95% 0·67-1·00; p=0·04). Serious adverse events occurred in 99 (6%) of 1573 patients taking lapatinib and 77 (5%) of 1574 patients taking placebo, with higher incidences of grade 3-4 diarrhoea (97 [6%] vs nine [<1%]), rash (72 [5%] vs three [<1%]), and hepatobiliary disorders (36 [2%] vs one [<1%]).Our data show that there was no significant difference in disease-free survival between groups when analysed in the intention-to-treat population. However, exploratory analyses restricted to patients who had HER2-positive disease confirmed by central fluorescence in-situ hybridisation review suggested marginal benefit with lapatinib in terms of disease-free survival. Thus lapatinib might be an option for women with HER2-positive breast cancer who do not or cannot receive adjuvant trastuzumab.GlaxoSmithKline." @default.
• W2162854541 created "2016-06-24" @default.
• W2162854541 creator A5009675926 @default.
• W2162854541 creator A5012804079 @default.
• W2162854541 creator A5017550097 @default.
• W2162854541 creator A5019992117 @default.
• W2162854541 creator A5033494478 @default.
• W2162854541 creator A5034630560 @default.
• W2162854541 creator A5035383163 @default.
• W2162854541 creator A5035387502 @default.
• W2162854541 creator A5047440506 @default.
• W2162854541 creator A5049907389 @default.
• W2162854541 creator A5061114358 @default.
• W2162854541 creator A5066135773 @default.
• W2162854541 creator A5067552665 @default.
• W2162854541 creator A5071073989 @default.
• W2162854541 creator A5071158497 @default.
• W2162854541 creator A5071432873 @default.
• W2162854541 creator A5083168171 @default.
• W2162854541 creator A5083470051 @default.
• W2162854541 creator A5090510186 @default.
• W2162854541 date "2013-01-01" @default.
• W2162854541 modified "2023-10-12" @default.
• W2162854541 title "Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial" @default.
• W2162854541 cites W1925211454 @default.
• W2162854541 cites W1987326983 @default.
• W2162854541 cites W2009878678 @default.
• W2162854541 cites W2022102157 @default.
• W2162854541 cites W2096884232 @default.
• W2162854541 cites W2097698108 @default.
• W2162854541 cites W2098775844 @default.
• W2162854541 cites W2099630695 @default.
• W2162854541 cites W2110444464 @default.
• W2162854541 cites W2111578514 @default.
• W2162854541 cites W2123591186 @default.
• W2162854541 cites W2124370104 @default.
• W2162854541 cites W2125620887 @default.
• W2162854541 cites W2130034035 @default.
• W2162854541 cites W2132893003 @default.
• W2162854541 cites W2133347950 @default.
• W2162854541 cites W2140055441 @default.
• W2162854541 cites W2140354367 @default.
• W2162854541 cites W2141393790 @default.
• W2162854541 cites W2146384083 @default.
• W2162854541 cites W2149847697 @default.
• W2162854541 cites W2150086065 @default.
• W2162854541 cites W2156677665 @default.
• W2162854541 doi "https://doi.org/10.1016/s1470-2045(12)70508-9" @default.
• W2162854541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23234763" @default.
• W2162854541 hasPublicationYear "2013" @default.
• W2162854541 type Work @default.
• W2162854541 sameAs 2162854541 @default.
• W2162854541 citedByCount "123" @default.
• W2162854541 countsByYear W21628545412013 @default.
• W2162854541 countsByYear W21628545412014 @default.
• W2162854541 countsByYear W21628545412015 @default.
• W2162854541 countsByYear W21628545412016 @default.
• W2162854541 countsByYear W21628545412017 @default.
• W2162854541 countsByYear W21628545412018 @default.
• W2162854541 countsByYear W21628545412019 @default.
• W2162854541 countsByYear W21628545412020 @default.
• W2162854541 countsByYear W21628545412021 @default.
• W2162854541 countsByYear W21628545412022 @default.
• W2162854541 countsByYear W21628545412023 @default.
• W2162854541 crossrefType "journal-article" @default.
• W2162854541 hasAuthorship W2162854541A5009675926 @default.
• W2162854541 hasAuthorship W2162854541A5012804079 @default.
• W2162854541 hasAuthorship W2162854541A5017550097 @default.
• W2162854541 hasAuthorship W2162854541A5019992117 @default.
• W2162854541 hasAuthorship W2162854541A5033494478 @default.
• W2162854541 hasAuthorship W2162854541A5034630560 @default.
• W2162854541 hasAuthorship W2162854541A5035383163 @default.
• W2162854541 hasAuthorship W2162854541A5035387502 @default.
• W2162854541 hasAuthorship W2162854541A5047440506 @default.
• W2162854541 hasAuthorship W2162854541A5049907389 @default.
• W2162854541 hasAuthorship W2162854541A5061114358 @default.
• W2162854541 hasAuthorship W2162854541A5066135773 @default.
• W2162854541 hasAuthorship W2162854541A5067552665 @default.
• W2162854541 hasAuthorship W2162854541A5071073989 @default.
• W2162854541 hasAuthorship W2162854541A5071158497 @default.
• W2162854541 hasAuthorship W2162854541A5071432873 @default.
• W2162854541 hasAuthorship W2162854541A5083168171 @default.
• W2162854541 hasAuthorship W2162854541A5083470051 @default.
• W2162854541 hasAuthorship W2162854541A5090510186 @default.
• W2162854541 hasConcept C121608353 @default.
• W2162854541 hasConcept C126322002 @default.
• W2162854541 hasConcept C142724271 @default.
• W2162854541 hasConcept C143998085 @default.
• W2162854541 hasConcept C168563851 @default.
• W2162854541 hasConcept C203092338 @default.
• W2162854541 hasConcept C204787440 @default.
• W2162854541 hasConcept C207103383 @default.
• W2162854541 hasConcept C27081682 @default.
• W2162854541 hasConcept C2777329042 @default.
• W2162854541 hasConcept C2779786085 @default.
• W2162854541 hasConcept C2908647359 @default.
• W2162854541 hasConcept C44249647 @default.
• W2162854541 hasConcept C530470458 @default.

• next